Cargando…
Targeting β2-Adrenergic Receptors Shows Therapeutical Benefits in Clear Cell Renal Cell Carcinoma from Von Hippel–Lindau Disease
Von Hippel–Lindau (VHL), is a rare autosomal dominant inherited cancer in which the lack of VHL protein triggers the development of multisystemic tumors such us retinal hemangioblastomas (HB), CNS-HB, and clear cell renal cell carcinoma (ccRCC). ccRCC ranks third in terms of incidence and first in c...
Autores principales: | Albiñana, Virginia, Gallardo-Vara, Eunate, de Rojas-P, Isabel, Recio-Poveda, Lucia, Aguado, Tania, Canto-Cano, Ana, Aguirre, Daniel T., Serra, Marcelo M., González-Peramato, Pilar, Martínez-Piñeiro, Luis, Cuesta, Angel M., Botella, Luisa Maria |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563408/ https://www.ncbi.nlm.nih.gov/pubmed/32854260 http://dx.doi.org/10.3390/jcm9092740 |
Ejemplares similares
-
The β2-adrenergic receptor antagonist ICI-118,551 blocks the constitutively activated HIF signalling in hemangioblastomas from von Hippel-Lindau disease
por: Cuesta, A. M., et al.
Publicado: (2019) -
The Endothelial Landscape and Its Role in Von Hippel–Lindau Disease
por: de Rojas-P, Isabel, et al.
Publicado: (2021) -
Blockade of β2-Adrenergic Receptor Reduces Inflammation and Oxidative Stress in Clear Cell Renal Cell Carcinoma
por: Albiñana, Virginia, et al.
Publicado: (2022) -
Repurposing propranolol as a drug for the treatment of retinal haemangioblastomas in von Hippel-Lindau disease
por: Albiñana, Virginia, et al.
Publicado: (2017) -
Evaluation of the safety and effectiveness of oral propranolol in patients with von Hippel-Lindau disease and retinal hemangioblastomas: phase III clinical trial
por: González-Rodríguez, Beatriz, et al.
Publicado: (2019)